Skip to main content
ALNYLAM PHARMACEUTICALS, INC. logo

ALNYLAM PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · ALNY ISIN · US72703U1025 LEI · 529900S3ZI14OWRJII50 US Manufacturing
Open in API
Filings indexed 1,232 across all filing types
Latest filing 2026-05-27 Board/Management Inform…
Country US United States of America
Listing US ALNY

About ALNYLAM PHARMACEUTICALS, INC.

https://www.alnylam.com/

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company that pioneers and leads the development of RNA interference (RNAi) therapeutics. The company is dedicated to translating the science of RNAi into a new class of innovative medicines. Its core activities encompass the research, development, manufacturing, and commercialization of therapies that utilize RNAi's natural biological process of gene silencing to target the genetic drivers of disease. This approach offers a novel mechanism for treating a range of debilitating conditions, with a focus on delivering transformational medicines to patients.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 85% confidence The document is an SEC Form 8-K “Current Report” focusing on Item 5.02 (board expansion and election of a new director, including compensatory arrangements) and Item 5.07 (the submission of matters to a vote of security holders). The initial and primary disclosure is the election and appointment of a new board member and related director compensation, constituting an announcement of changes in the company’s board of directors. This matches the “Board/Management Information” category (Code: MANG).
2026-05-27 English
8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
Earnings Release Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 30, 2026, reporting the company's financial results for the quarter ended March 31, 2026. It specifically references Item 2.02 "Results of Operations and Financial Condition" and includes a press release as Exhibit 99.1. The document states that the press release is furnished, not filed, and the text is relatively short (3740 characters). This is a typical format for an Earnings Release announcement via Form 8-K, which is an initial announcement of quarterly financial results with key highlights. It is not a full quarterly report (which would be an IR), nor an annual report (10-K). Therefore, the correct classification is Earnings Release (ER).
2026-04-30 English
ARS - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
Annual Report
2026-04-06 English
DEF 14A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
Proxy Solicitation & Information Statement
2026-04-06 English
SCHEDULE 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
Major Shareholding Notification
2026-03-26 English
4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
Director's Dealing
2026-03-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.